TY - JOUR AU - McGhee, D. J. AU - Ritchie, C. W. AU - Thompson, P. A. AU - Wright, D. E. AU - Zajicek, J. P. AU - Counsell, C. E. PY - 2014 DA - 2014// TI - A systematic review of biomarkers for disease progression in Alzheimer's disease JO - PLoS One. VL - 9 UR - https://doi.org/10.1371/journal.pone.0088854 DO - 10.1371/journal.pone.0088854 ID - McGhee2014 ER - TY - JOUR AU - McGhee, D. J. AU - Royle, P. L. AU - Thompson, P. A. AU - Wright, D. E. AU - Zajicek, J. P. AU - Counsell, C. E. PY - 2013 DA - 2013// TI - A systematic review of biomarkers for disease progression in Parkinson's disease JO - BMC Neurol. VL - 13 UR - https://doi.org/10.1186/1471-2377-13-35 DO - 10.1186/1471-2377-13-35 ID - McGhee2013 ER - TY - JOUR AU - Clarke, C. E. PY - 2004 DA - 2004// TI - A "cure" for Parkinson's disease: can neuroprotection be proven with current trial designs? JO - Mov Disord. VL - 19 UR - https://doi.org/10.1002/mds.20057 DO - 10.1002/mds.20057 ID - Clarke2004 ER - TY - JOUR AU - Rascol, O. PY - 2009 DA - 2009// TI - "Disease-modification" trials in Parkinson disease: target populations, endpoints and study design JO - Neurology. VL - 72 UR - https://doi.org/10.1212/WNL.0b013e318199049e DO - 10.1212/WNL.0b013e318199049e ID - Rascol2009 ER - TY - JOUR AU - Clarke, C. E. PY - 2008 DA - 2008// TI - Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed? JO - Mov Disord. VL - 23 UR - https://doi.org/10.1002/mds.21918 DO - 10.1002/mds.21918 ID - Clarke2008 ER - TY - JOUR AU - Hart, R. G. AU - Pearce, L. A. AU - Ravina, B. M. AU - Yaltho, T. C. AU - Marler, J. R. PY - 2009 DA - 2009// TI - Neuroprotection trials in Parkinson's disease: systematic review JO - Mov Disord VL - 24 UR - https://doi.org/10.1002/mds.22432 DO - 10.1002/mds.22432 ID - Hart2009 ER - TY - STD TI - Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE: sensitivity-maximizing version (2008) revision; OVID format. Cochrane Handbook for Systematic Reviews of Interventions. Edited by Higgins J, Green S. 2011. The Cochrane Collaboration. http://handbook.cochrane.org/. Accessed 14 Oct 2015. UR - http://handbook.cochrane.org/ ID - ref7 ER - TY - JOUR AU - Lefebvre, C. AU - Eisinga, A. AU - McDonald, S. AU - Paul, N. PY - 2008 DA - 2008// TI - Enhancing access to reports of randomized trials published world-wide--the contribution of EMBASE records to the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library JO - Emerg Themes Epidemiol. VL - 5 UR - https://doi.org/10.1186/1742-7622-5-13 DO - 10.1186/1742-7622-5-13 ID - Lefebvre2008 ER - TY - JOUR PY - 2006 DA - 2006// TI - A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease JO - Neurology. VL - 66 UR - https://doi.org/10.1212/01.wnl.0000201252.57661.e1 DO - 10.1212/01.wnl.0000201252.57661.e1 ID - ref9 ER - TY - JOUR PY - 2007 DA - 2007// TI - A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease JO - Neurology. VL - 68 UR - https://doi.org/10.1212/01.wnl.0000250355.28474.8e DO - 10.1212/01.wnl.0000250355.28474.8e ID - ref10 ER - TY - JOUR AU - Schwarzschild, M. A. AU - Ascherio, A. AU - Beal, M. F. AU - Cudkowicz, M. E. AU - Curhan, G. C. AU - Hare, J. M. PY - 2014 DA - 2014// TI - Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial JO - JAMA Neurol. VL - 71 UR - https://doi.org/10.1001/jamaneurol.2013.5528 DO - 10.1001/jamaneurol.2013.5528 ID - Schwarzschild2014 ER - TY - STD TI - NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators. Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. Lancet Neurol. 2015;14:795–803. ID - ref12 ER - TY - JOUR AU - Folstein, M. F. AU - Folstein, S. E. AU - McHugh, P. R. PY - 1975 DA - 1975// TI - "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician JO - J Psychiatr Res VL - 12 UR - https://doi.org/10.1016/0022-3956(75)90026-6 DO - 10.1016/0022-3956(75)90026-6 ID - Folstein1975 ER - TY - JOUR AU - Mohs, R. C. AU - Knopman, D. AU - Petersen, R. C. AU - Ferris, S. H. AU - Ernesto, C. AU - Grundman, M. PY - 1997 DA - 1997// TI - Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study JO - Alzheimer Dis Assoc Disord VL - 11 UR - https://doi.org/10.1097/00002093-199700112-00003 DO - 10.1097/00002093-199700112-00003 ID - Mohs1997 ER - TY - JOUR AU - Morris, J. C. PY - 1993 DA - 1993// TI - The Clinical Dementia Rating (CDR): current version and scoring rules JO - Neurology. VL - 43 UR - https://doi.org/10.1212/WNL.43.11.2412-a DO - 10.1212/WNL.43.11.2412-a ID - Morris1993 ER - TY - JOUR AU - Aviles-Olmos, I. AU - Dickson, J. AU - Kefalopoulou, Z. AU - Djamshidian, A. AU - Ell, P. AU - Soderlund, T. PY - 2013 DA - 2013// TI - Exenatide and the treatment of patients with Parkinson's disease JO - J Clin Invest. VL - 123 UR - https://doi.org/10.1172/JCI68295 DO - 10.1172/JCI68295 ID - Aviles-Olmos2013 ER - TY - JOUR AU - Goetz, C. G. AU - Poewe, W. AU - Rascol, O. AU - Sampaio, C. AU - Stebbins, G. T. AU - Counsell, C. PY - 2004 DA - 2004// TI - Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations JO - Mov Disord. VL - 19 UR - https://doi.org/10.1002/mds.20213 DO - 10.1002/mds.20213 ID - Goetz2004 ER - TY - CHAP AU - Fahn, S. AU - Eton, R. L. ED - Fahn, S. ED - Marsden, C. D. ED - Calne, D. PY - 1987 DA - 1987// TI - The Unified Parkinson's Disease Rating Scale BT - Recent Developments in Parkinson's Disease PB - Macmillan Healthcare Information CY - Florham Park, New Jersey ID - Fahn1987 ER - TY - JOUR AU - Green, R. C. AU - Schneider, L. S. AU - Amato, D. A. AU - Beelen, A. P. AU - Wilcock, G. AU - Swabb, E. A. PY - 2009 DA - 2009// TI - Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial JO - JAMA. VL - 302 UR - https://doi.org/10.1001/jama.2009.1866 DO - 10.1001/jama.2009.1866 ID - Green2009 ER - TY - JOUR PY - 1996 DA - 1996// TI - Effect of lazabemide on the progression of disability in early Parkinson's disease JO - Ann Neurol VL - 40 UR - https://doi.org/10.1002/ana.410400116 DO - 10.1002/ana.410400116 ID - ref20 ER - TY - JOUR AU - Olanow, C. W. AU - Rascol, O. AU - Hauser, R. AU - Feigin, P. D. AU - Jankovic, J. AU - Lang, A. PY - 2009 DA - 2009// TI - A double-blind, delayed-start trial of rasagiline in Parkinson's disease JO - N Eng J Med. VL - 361 UR - https://doi.org/10.1056/NEJMoa0809335 DO - 10.1056/NEJMoa0809335 ID - Olanow2009 ER - TY - JOUR AU - Sano, M. AU - Ernesto, C. AU - Thomas, R. G. AU - Klauber, M. R. AU - Schafer, K. AU - Grundman, M. PY - 1997 DA - 1997// TI - A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study JO - New Engl J Med VL - 336 UR - https://doi.org/10.1056/NEJM199704243361704 DO - 10.1056/NEJM199704243361704 ID - Sano1997 ER - TY - JOUR AU - Tariot, P. N. AU - Schneider, L. S. AU - Cummings, J. AU - Thomas, R. G. AU - Raman, R. AU - Jakimovich, L. J. PY - 2011 DA - 2011// TI - Alzheimer's Disease Cooperative Study Group. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease JO - Arch Gen Psychiatry VL - 68 UR - https://doi.org/10.1001/archgenpsychiatry.2011.72 DO - 10.1001/archgenpsychiatry.2011.72 ID - Tariot2011 ER - TY - STD TI - Sunphenon EGCg (Epigallocatechin-Gallate) in the early stage of Alzheimer's disease (SUN-AK). ClinicalTrials.gov. 2015. http://www.clinicaltrials.gov/ct2/show/NCT00951834. Accessed 22 Sep 2015. UR - http://www.clinicaltrials.gov/ct2/show/NCT00951834 ID - ref24 ER - TY - JOUR AU - Aisen, P. S. AU - Schafer, K. A. AU - Grundman, M. AU - Pfeiffer, E. AU - Sano, M. AU - Davis, K. L. PY - 2003 DA - 2003// TI - Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial JO - JAMA. VL - 289 UR - https://doi.org/10.1001/jama.289.21.2819 DO - 10.1001/jama.289.21.2819 ID - Aisen2003 ER - TY - JOUR PY - 1993 DA - 1993// TI - Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease JO - N Eng J Med VL - 328 UR - https://doi.org/10.1056/NEJM199301213280305 DO - 10.1056/NEJM199301213280305 ID - ref26 ER - TY - JOUR AU - Fowler, J. S. AU - Volkow, N. D. AU - Logan, J. AU - Wang, G. J. AU - MacGregor, R. R. AU - Schyler, D. PY - 1994 DA - 1994// TI - Slow recovery of human brain MAO B after L-deprenyl (Selegeline) withdrawal JO - Synapse. VL - 18 UR - https://doi.org/10.1002/syn.890180203 DO - 10.1002/syn.890180203 ID - Fowler1994 ER - TY - JOUR AU - Tetrud, J. W. AU - Langston, J. W. PY - 1989 DA - 1989// TI - The effect of deprenyl (selegiline) on the natural history of Parkinson's disease JO - Science. VL - 245 UR - https://doi.org/10.1126/science.2502843 DO - 10.1126/science.2502843 ID - Tetrud1989 ER - TY - JOUR AU - Cummings, J. L. PY - 2006 DA - 2006// TI - Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials JO - Alzheimers Dement. VL - 2 UR - https://doi.org/10.1016/j.jalz.2006.07.001 DO - 10.1016/j.jalz.2006.07.001 ID - Cummings2006 ER - TY - JOUR AU - Schapira, A. H. AU - Obeso, J. PY - 2006 DA - 2006// TI - Timing of treatment initiation in Parkinson's disease: a need for reappraisal? JO - Ann Neurol. VL - 59 UR - https://doi.org/10.1002/ana.20789 DO - 10.1002/ana.20789 ID - Schapira2006 ER - TY - JOUR AU - Olanow, C. W. AU - Rascol, O. PY - 2010 DA - 2010// TI - The delayed-start study in Parkinson disease: can't satisfy everyone JO - Neurology. VL - 74 UR - https://doi.org/10.1212/WNL.0b013e3181d7d94b DO - 10.1212/WNL.0b013e3181d7d94b ID - Olanow2010 ER - TY - JOUR AU - Xiong, C. AU - Belle, G. AU - Miller, J. P. AU - Morris, J. C. PY - 2011 DA - 2011// TI - Designing clinical trials to test disease-modifying agents: application to the treatment trials of Alzheimer's disease JO - Clin Trials VL - 8 UR - https://doi.org/10.1177/1740774510392391 DO - 10.1177/1740774510392391 ID - Xiong2011 ER - TY - JOUR AU - D'Agostino, R. B. PY - 2009 DA - 2009// TI - The delayed-start study design JO - N Engl J Med. VL - 361 UR - https://doi.org/10.1056/NEJMsm0904209 DO - 10.1056/NEJMsm0904209 ID - D'Agostino2009 ER - TY - JOUR AU - Evans, J. R. AU - Barker, R. A. PY - 2011 DA - 2011// TI - Defining meaningful outcome measures in trials of disease-modifying therapies in Parkinson's disease JO - Expert Opin Pharmacother. VL - 12 UR - https://doi.org/10.1517/14656566.2011.548807 DO - 10.1517/14656566.2011.548807 ID - Evans2011 ER - TY - JOUR AU - Karran, E. AU - Hardy, J. PY - 2014 DA - 2014// TI - A critique of the drug discovery and phase 3 clincial programs targeting the amyloid hypothesis for Alzheimer disease JO - Ann Neurol. VL - 76 UR - https://doi.org/10.1002/ana.24188 DO - 10.1002/ana.24188 ID - Karran2014 ER - TY - STD TI - Chakraborty H, Gu H. A mixed model approach for intent-to-treat analysis in longitudinal clinical trials with missing values. RTI Press. 2009. http://www.rti.org/rtipress (Publication No. MR-0009-0903). Accessed 14 Oct 2015. UR - http://www.rti.org/rtipress ID - ref36 ER - TY - JOUR AU - Schwartz, D. AU - Lellouch, J. PY - 1967 DA - 1967// TI - Explanatory and pragmatic attitudes in therapeutical trials JO - J Chronic Dis. VL - 20 UR - https://doi.org/10.1016/0021-9681(67)90041-0 DO - 10.1016/0021-9681(67)90041-0 ID - Schwartz1967 ER - TY - JOUR AU - Hollis, S. AU - Campbell, F. PY - 1999 DA - 1999// TI - What is meant by intention to treat analysis? Survey of published randomised controlled trials JO - BMJ. VL - 319 UR - https://doi.org/10.1136/bmj.319.7211.670 DO - 10.1136/bmj.319.7211.670 ID - Hollis1999 ER - TY - JOUR AU - Shults, C. W. AU - Oakes, D. AU - Kieburtz, K. AU - Beal, M. F. AU - Haas, R. AU - Plumb, S. PY - 2002 DA - 2002// TI - Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline JO - Arch Neurol. VL - 59 UR - https://doi.org/10.1001/archneur.59.10.1541 DO - 10.1001/archneur.59.10.1541 ID - Shults2002 ER - TY - JOUR AU - White, I. R. AU - Horton, N. J. AU - Carpenter, J. AU - Pocock, S. J. PY - 2011 DA - 2011// TI - Strategy for intention to treat analysis in randomised trials with missing outcome data JO - BMJ. VL - 342 UR - https://doi.org/10.1136/bmj.d40 DO - 10.1136/bmj.d40 ID - White2011 ER - TY - JOUR AU - McGhee, D. AU - Parker, A. AU - Fielding, S. AU - Zajicek, J. AU - Counsell, C. PY - 2015 DA - 2015// TI - Using ‘dead or dependent’ as an outcome measure in clincial trials in Parkinson’s disease JO - J Neurol Neurosurg Psychiatry. VL - 86 UR - https://doi.org/10.1136/jnnp-2014-307703 DO - 10.1136/jnnp-2014-307703 ID - McGhee2015 ER - TY - STD TI - European Study of 3APS in Mild to Moderate Alzheimer's Disease Patients. 2007. ClinicalTrials.gov. http://www.clinicaltrials.gov/ct2/show/NCT00217763. Accessed 9 Oct 2015. UR - http://www.clinicaltrials.gov/ct2/show/NCT00217763 ID - ref42 ER -